Deciphera Pharmaceuticals Llc Stock Profit Margin
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
Deciphera |
Deciphera Pharmaceuticals LLC Company Profit Margin Analysis
Deciphera Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Deciphera Pharmaceuticals Profit Margin | (1.09) % |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Deciphera Pharmaceuticals LLC has a Profit Margin of -1.0887%. This is 90.29% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 14.28% lower than that of the firm.
Deciphera Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Deciphera Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| Gross Profit | (62.55 M) | |||
| EBITDA | (210.96 M) | |||
| Net Income | (194.94 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Short Ratio | 1.05 X | |||
| Earnings Per Share | (2.21) X | |||
| Price To Earnings To Growth | (0.32) X | |||
| Target Price | 27.52 | |||
| Number Of Employees | 355 | |||
| Beta | 0.18 | |||
| Market Capitalization | 2.21 B | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Working Capital | 280.82 M | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
| Net Asset | 473.57 M |
About Deciphera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Deciphera Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deciphera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deciphera Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |